Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cepheid (NASDAQ:CPHD)

52.63
Delayed Data
As of Sep 27
 0.00 / 0.00%
Today’s Change
25.09
Today|||52-Week Range
53.91
+44.07%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$3.8B

Company Description

Cepheid operates as a molecular diagnostics company, which develops, manufactures, and markets fully-integrated systems for testing in the clinical market, as well as for application in the company's legacy industrial, biothreat, and partner markets. The company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. It operates through the GeneXpert and SmartCycler principal systems. The GeneXpert system integrates sample preparation in addition to deoxyribonucleic acid (DNA) amplification and detection. This system is designed for a broad range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. The company was founded by Thomas L. Gutshall, William McMillan, Kurt Petersen, Greg Kovacs, and M. Allen Northrup on March 4, 1996 and is headquartered in Sunnyvale, CA.

Contact Information

Cepheid
904 Caribbean Drive
Sunnyvale California 94089-1189
P:(408) 541-4191
Investor Relations:
(408) 400-8329

Employees

Shareholders

Mutual fund holders59.05%
Other institutional35.52%
Individual stakeholders3.81%

Top Executives

John L. BishopChairman & Chief Executive Officer
Warren C. KocmondPresident & Chief Operating Officer
Daniel E. MaddenChief Financial & Principal Accounting Officer
David H. PersingClass II Director & Chief Medical Officer
William E. MurrayChief Privacy Officer, EVP & General Counsel